• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

EPO 受体中的一个遗传获得性功能风险等位基因使个体易患家族性 JAK2 骨髓增殖性肿瘤。

An inherited gain-of-function risk allele in EPOR predisposes to familial JAK2 myeloproliferative neoplasms.

机构信息

INSERM, UMR1287, Villejuif, France.

Gustave Roussy, Villejuif, France.

出版信息

Br J Haematol. 2022 Jul;198(1):131-136. doi: 10.1111/bjh.18165. Epub 2022 Mar 30.

DOI:10.1111/bjh.18165
PMID:35355248
Abstract

Myeloproliferative neoplasms (MPN) are mainly sporadic but inherited variants have been associated with higher risk development. Here, we identified an EPOR variant (EPOR ) in a large family diagnosed with JAK2 -positive polycythaemia vera (PV) or essential thrombocytosis (ET). We investigated its functional impact on JAK2 clonal amplification in patients and found that the variant allele fraction (VAF) was low in PV progenitors but increase strongly in mature cells. Moreover, we observed that EPOR alone induced a constitutive phosphorylation of STAT5 in cell lines or primary cells. Overall, this study points for searching inherited-risk alleles affecting the JAK2/STAT pathway in MPN.

摘要

骨髓增殖性肿瘤(MPN)主要为散发性,但已发现遗传性变异与更高的发病风险相关。在此,我们在一个被诊断为 JAK2 阳性真性红细胞增多症(PV)或原发性血小板增多症(ET)的大家族中发现了一个 EPOR 变异(EPOR )。我们研究了它对患者 JAK2 克隆扩增的功能影响,发现变异等位基因分数(VAF)在 PV 祖细胞中较低,但在成熟细胞中强烈增加。此外,我们观察到 EPOR 单独诱导细胞系或原代细胞中 STAT5 的组成性磷酸化。总的来说,这项研究指出了在 MPN 中寻找影响 JAK2/STAT 通路的遗传风险等位基因。

相似文献

1
An inherited gain-of-function risk allele in EPOR predisposes to familial JAK2 myeloproliferative neoplasms.EPO 受体中的一个遗传获得性功能风险等位基因使个体易患家族性 JAK2 骨髓增殖性肿瘤。
Br J Haematol. 2022 Jul;198(1):131-136. doi: 10.1111/bjh.18165. Epub 2022 Mar 30.
2
Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.促红细胞生成素受体中的三个酪氨酸残基对Janus激酶2 V617F突变体诱导的肿瘤发生至关重要。
J Biol Chem. 2017 Feb 3;292(5):1826-1846. doi: 10.1074/jbc.M116.749465. Epub 2016 Dec 20.
3
Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.骨髓增殖性疾病诊断标准的概念变迁以及骨髓增殖性肿瘤的分子病因学与分类:从1950年的达梅谢克到2005年的万琴克尔及以后
Acta Haematol. 2015;133(1):36-51. doi: 10.1159/000358580. Epub 2014 Aug 7.
4
Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.儿童真性红细胞增多症和原发性血小板增多症中骨髓增殖性疾病的标志物。
J Clin Oncol. 2007 Mar 20;25(9):1048-53. doi: 10.1200/JCO.2006.08.6884.
5
[Myeloproliferative diseases caused by JAK2 mutation].由JAK2突变引起的骨髓增殖性疾病
Rinsho Byori. 2009 Apr;57(4):357-64.
6
Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.Janus 激酶 2 V617F 等位基因负担与骨髓增殖性肿瘤临床血液学参数的相关性。
Ann Lab Med. 2012 Nov;32(6):385-91. doi: 10.3343/alm.2012.32.6.385. Epub 2012 Oct 17.
7
TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.TERT rs2736100 A>C SNP 和 JAK2 46/1 单倍型显著导致 JAK2 V617F 和 CALR 突变的骨髓增殖性肿瘤的发生——一项对 529 例患者的多中心研究。
Br J Haematol. 2016 Jul;174(2):218-26. doi: 10.1111/bjh.14041. Epub 2016 Apr 7.
8
The multi-site docking protein Gab1 is constitutively phosphorylated independent from its recruitment to the plasma membrane in Jak2-V617F-positive cells and mediates proliferation of human erythroleukaemia cells.多位点对接蛋白Gab1在Jak2-V617F阳性细胞中不依赖于其募集到质膜而组成性磷酸化,并介导人红白血病细胞的增殖。
Cell Signal. 2017 Jul;35:37-47. doi: 10.1016/j.cellsig.2017.03.021. Epub 2017 Mar 30.
9
Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens.JAK2 V617F 阳性骨髓增殖性疾病中的表型变异性:祖细胞和中性粒细胞等位基因负荷的作用。
Exp Hematol. 2008 Nov;36(11):1480-6. doi: 10.1016/j.exphem.2008.05.006. Epub 2008 Aug 23.
10
Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.采用熔解曲线分析快速鉴定骨髓增殖性肿瘤中的杂合或纯合 JAK2(V617F)突变。
J Formos Med Assoc. 2012 Jan;111(1):34-40. doi: 10.1016/j.jfma.2012.01.003. Epub 2012 Feb 1.

引用本文的文献

1
New approaches to standard of care in early-phase myeloproliferative neoplasms: can interferon-α alter the natural history of the disease?早期骨髓增殖性肿瘤护理标准的新方法:α干扰素能否改变疾病的自然病程?
Haematologica. 2025 Apr 1;110(4):850-862. doi: 10.3324/haematol.2023.283958. Epub 2024 Oct 24.
2
Myeloproliferative Neoplasms: Diseases Mediated by Chronic Activation of Signal Transducer and Activator of Transcription (STAT) Proteins.骨髓增殖性肿瘤:由信号转导子和转录激活子(STAT)蛋白的慢性激活介导的疾病
Cancers (Basel). 2024 Jan 11;16(2):313. doi: 10.3390/cancers16020313.
3
Mutations, inflammation and phenotype of myeloproliferative neoplasms.
骨髓增殖性肿瘤的突变、炎症与表型
Front Oncol. 2023 May 22;13:1196817. doi: 10.3389/fonc.2023.1196817. eCollection 2023.
4
Phenotypic screening models for rapid diagnosis of genetic variants and discovery of personalized therapeutics.用于快速诊断遗传变异和发现个体化治疗方法的表型筛选模型。
Mol Aspects Med. 2023 Jun;91:101153. doi: 10.1016/j.mam.2022.101153. Epub 2022 Nov 18.
5
Genetic basis and molecular profiling in myeloproliferative neoplasms.骨髓增殖性肿瘤的遗传基础和分子谱分析。
Blood. 2023 Apr 20;141(16):1909-1921. doi: 10.1182/blood.2022017578.